Miskolc, Hungary Clinical Trials

A listing of Miskolc, Hungary clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 71 clinical trials
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Endomedix Diagnosztikai Kozpont
 (1.1 away) Contact site
  • 13 Jun, 2021
  • +903 other locations
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

stage iv non-small cell lung cancer
cancer chemotherapy
lung carcinoma
epidermal growth factor receptor
CRU Hungary Egeszsegugyi s Szolgaltato Kft. /ID# 204878
 (0.8 away) Contact site
  • 03 Jun, 2021
  • +278 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

estrogen receptor
epidermal growth factor receptor
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 2904)
 (1.4 away) Contact site
  • 13 Jun, 2021
  • +285 other locations
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared …

stereotactic body radiation therapy
lung carcinoma
CRU Hungary KFT ( Site 2309)
 (0.8 away) Contact site
  • 14 Jun, 2021
  • +172 other locations
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

myocardial infarction
arterial disease
Research Site
 (0.8 away) Contact site
  • 12 Jun, 2021
  • +1329 other locations
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha …

rheumatoid factor
tumour necrosis
tumor necrosis factor
tumor necrosis factor alpha
Complex Medical Centre - D li Klinika
 (90.5 away) Contact site
  • 27 Jan, 2021
  • +34 other locations
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

The study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy.

early parkinson's
Borsod-Aba j-Zempl n Megyei K rh z s Egyetemi Oktat K rh z Neurol giai s Pszichi triai Int zet
 (1.4 away) Contact site
  • 01 Mar, 2021
  • +127 other locations
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain Caused by Bleeding Onto the Surface of the Brain

This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.

BAZ Megyei K rh z s Egyetemi Oktat K rh z Neuroradiol giai s angiogr phi s oszt ly
 (1.4 away) Contact site
  • 08 May, 2021
  • +222 other locations
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline …

chronic migraine
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz
 (0.8 away) Contact site
  • 13 Jun, 2021
  • +169 other locations
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these …

clostridium difficile
antibiotic therapy
CRU Hungary Kft.
 (0.8 away) Contact site
  • 16 Apr, 2021
  • +257 other locations